All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
Featured:
Miguel-Angel PeralesDuring the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub was pleased to speak with Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does prior use of checkpoint inhibitors impact allogeneic stem cell transplantation outcomes for patients with Hodgkin lymphoma?
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
Perales begins by discussing the new therapies that have become available in the past decade to treat Hodgkin lymphoma, such as rituximab and checkpoint inhibitors. This is followed by a summary of the joint study between the Center for International Blood and Marrow Transplant Research (CIBMTR) and EBMT, which aimed to investigate if receiving a checkpoint inhibitor prior to allogeneic transplant impacted progression-free and overall survival in patients with Hodgkin lymphoma. Perales finishes by discussing the importance of having a curative approach available.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?